Nguyen, Rosa http://orcid.org/0000-0001-5143-2055
Sahr, Natasha
Sykes, April
McCarville, Mary Beth
Federico, Sara M
Sooter, Amanda
Cullins, David
Rooney, Barbara
Janssen, William E
Talleur, Aimee C
Triplett, Brandon M
Anthony, Gwendolyn
Dyer, Michael A
Pappo, Alberto S
Leung, Wing H
Furman, Wayne L
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
https://doi.org/10.1136/jitc-2020-000590
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
https://doi.org/10.1136/jitc-2019-000176
Documents that mention this clinical trial
Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
https://doi.org/10.1136/jitc-2020-000590
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
https://doi.org/10.1136/jitc-2019-000176
Documents that mention this clinical trial
Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
https://doi.org/10.1136/jitc-2020-000590
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
https://doi.org/10.1136/jitc-2019-000176
Funding for this research was provided by:
American Lebanese Syrian Associated Charities
Conquer Cancer Foundation (12822)
Press On Fund
National Institutes of Health (CA021765)